Gefitinib as first-line treatment for patients with NSCLC with activating EGFR mutationin exons 19 (Del19) or 21 (L858R) in the Czech Republic - Amsterdam 2015

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

International Congresses Amsterdam 2015

Lung cancer therapy: clinical trials

Chair(s): Konstantinos Zarogoulidis (Thessaloniki, Greece), Rainer G. Wiewrodt (Münster, Germany)

Session type: Poster Discussion

Gefitinib as first-line treatment for patients with NSCLC with activating EGFR mutationin exons 19 (Del19) or 21 (L858R) in the Czech Republic

Jana Skřičková (Brno, Czech Republic), Jana Skrickova, Zbynek Bortlicek, Karel Hejduk, Milos Pesek, Vitezslav Kolek, Leona Koubkova, Jaromir Roubec, Libor Havel, Frantisek Salajka, Marcela Tomiskova, Monika Satankova

EVENTS HOME

Limited Access

Please log in to myERS to view this content.

Don't have a myERS account? Register

Note: consult the ERS Respiratory Channel access rights page for more details.

CDN Connection Issue

The ERS International Congress 2015, Amsterdam

Limited Access

#{title}